Deal Details

BioDot Is Acquired By ATS

Healthcare
Industrial

BioDot, a portfolio company of Artemis, acquisition by ATS

Summary

BioDot, Inc. (“BioDot” or the “Company”), a portfolio company of Artemis Capital Partners (“Artemis”), was recently acquired by ATS Automation Tooling Systems Inc. (“ATS”) (TSX: ATA).

Baird served as the exclusive financial advisor to BioDot, Inc. on this transaction.

About

BioDot manufactures premium, non-contact and quantitative fluid dispensing systems serving customers in point-of-care and clinical diagnostics and other segments of the life sciences market. BioDot’s proprietary technology and patent portfolio allow it to meet stringent industry requirements and address customer needs in R&D, pilot production and rapid, high-volume production. Based in Irvine, California, BioDot has international offices to service a variety of industries in every nation.

Founded in 2010, Artemis Capital Partners is a private equity firm focused on acquiring and growing manufacturers of differentiated industrial technologies. Artemis seeks to partner with companies that have strong established management teams, outstanding engineering capabilities, unique products and expanding niche markets. Artemis is headquartered in Boston, Massachusetts.

ATS is an industry-leading automation solutions provider to many of the world's most successful companies. ATS uses its extensive knowledge base and global capabilities in custom automation, repeat automation, automation products and value-added services, including pre-automation and after-sales services, to address the sophisticated manufacturing automation systems and service needs of multinational customers in markets such as life sciences, food & beverage, transportation, consumer products and energy. Founded in 1978, ATS employs over 5,000 people at 28 manufacturing facilities and over 50 offices in North America, Europe, Southeast Asia and China. ATS is headquartered in Cambridge, Canada.